[go: up one dir, main page]

CY1110312T1 - Τοπικως εφαρμοσιμο φαρμακευτικο παρασκευασμα - Google Patents

Τοπικως εφαρμοσιμο φαρμακευτικο παρασκευασμα

Info

Publication number
CY1110312T1
CY1110312T1 CY20091100273T CY091100273T CY1110312T1 CY 1110312 T1 CY1110312 T1 CY 1110312T1 CY 20091100273 T CY20091100273 T CY 20091100273T CY 091100273 T CY091100273 T CY 091100273T CY 1110312 T1 CY1110312 T1 CY 1110312T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical preparation
locally applied
applied pharmaceutical
administering
inhibitor
Prior art date
Application number
CY20091100273T
Other languages
English (en)
Inventor
Christina Bolle
Rudolf Linder
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of CY1110312T1 publication Critical patent/CY1110312T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
    • F41B5/00—Bows; Crossbows
    • F41B5/12—Crossbows
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
    • F41B5/00—Bows; Crossbows
    • F41B5/12—Crossbows
    • F41B5/123—Compound crossbows
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
    • F41B5/00—Bows; Crossbows
    • F41B5/14—Details of bows; Accessories for arc shooting
    • F41B5/1442—Accessories for arc or bow shooting
    • F41B5/1469—Bow-string drawing or releasing devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Ένα τοπικό φαρμακευτικό παρασκεύασμα για χορήγηση ενός ελάχιστα διαλυτού αναστολέα PDE4 περιγράφεται. Απροσδόκητα καλή συστηματική βιοδιαθεσιμότητα παρατηρείται με αυτή τη δοσολογική μορφή.
CY20091100273T 2002-05-28 2009-03-10 Τοπικως εφαρμοσιμο φαρμακευτικο παρασκευασμα CY1110312T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10223828 2002-05-28
EP02011830 2002-05-28
DE10311613 2003-03-14
PCT/EP2003/005524 WO2003099334A1 (en) 2002-05-28 2003-05-27 Topically applicable pharmaceutical preparation

Publications (1)

Publication Number Publication Date
CY1110312T1 true CY1110312T1 (el) 2015-01-14

Family

ID=29587313

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20091100273T CY1110312T1 (el) 2002-05-28 2009-03-10 Τοπικως εφαρμοσιμο φαρμακευτικο παρασκευασμα
CY181101093T CY1121133T1 (el) 2002-05-28 2018-10-24 Τοπικα εφαρμοσιμο φαρμακευτικο παρασκευασμα

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY181101093T CY1121133T1 (el) 2002-05-28 2018-10-24 Τοπικα εφαρμοσιμο φαρμακευτικο παρασκευασμα

Country Status (33)

Country Link
US (7) US20060084684A1 (el)
EP (3) EP1511516B1 (el)
JP (3) JP5652983B2 (el)
KR (2) KR101307093B1 (el)
CN (3) CN101491520B (el)
AT (2) ATE485821T1 (el)
AU (2) AU2003240719B2 (el)
BR (2) BR0311337A (el)
CA (2) CA2486917C (el)
CY (2) CY1110312T1 (el)
DE (2) DE60325354D1 (el)
DK (3) DK1511516T3 (el)
EA (2) EA020569B1 (el)
ES (3) ES2354971T3 (el)
HK (2) HK1079437A1 (el)
HR (1) HRP20041211B1 (el)
HU (1) HUE039709T2 (el)
IL (3) IL164935A (el)
IS (1) IS2639B (el)
LT (1) LT2020243T (el)
MA (1) MA27813A1 (el)
ME (1) ME00565A (el)
MX (2) MXPA04011612A (el)
NO (2) NO334882B1 (el)
NZ (3) NZ536920A (el)
PL (3) PL211870B1 (el)
PT (3) PT1511481E (el)
RS (1) RS51104B (el)
SI (2) SI1511516T1 (el)
TR (1) TR201815573T4 (el)
UA (2) UA81910C2 (el)
WO (2) WO2003099334A1 (el)
ZA (2) ZA200408649B (el)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
CN101491520B (zh) * 2002-05-28 2011-03-16 尼科梅德有限责任公司 局部应用的药物制剂
EP1542768A1 (en) 2002-09-20 2005-06-22 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
FR2851247B1 (fr) * 2003-02-19 2007-06-29 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de pathologies degeneratives oculaires
DK1606261T3 (da) 2003-03-10 2010-01-18 Nycomed Gmbh Hidtil ukendt fremgangsmåde til fremstilling af roflumilast
JP2007517893A (ja) * 2004-01-10 2007-07-05 バイオリピッド インコーポレイテッド 脂質組成物及び該脂質組成物の使用方法
DE102004046236A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
DE102004046235A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
MX2007010560A (es) * 2005-03-08 2008-02-21 Nycomed Gmbh Roflumilast para el tratamiento de diabetes mellitus.
EP2258350B1 (en) * 2005-03-16 2014-12-24 Takeda GmbH Taste masked dosage form containing roflumilast
RU2007149249A (ru) * 2005-06-09 2009-07-20 Сантен Фармасьютикал Ко., Лтд (Jp) Глазные капли, содержащие рофлумиласт
AU2007218725B2 (en) 2006-02-21 2011-12-01 Eisai R & D Management Co., Ltd. 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative
AU2008215411B2 (en) 2007-02-16 2012-11-22 Eisai R & D Management Co., Ltd. Crystal, amorphous form and salt of methyl N-[3-(6,7-dimethoxy- 2-methylaminoquinazolin-4-yl)phenyl]terephthalamic acid
WO2009025239A1 (ja) 2007-08-17 2009-02-26 Eisai R & D Management Co., Ltd. 新規外用剤
CA2696727A1 (en) 2007-08-17 2009-02-26 Eisai R&D Management Co., Ltd. Method for producing quinazoline derivative
RU2012122169A (ru) 2009-10-30 2013-12-10 Нестек С.А. Способы поддержания здоровья глаз и облегчения глазных болезней у псовых
ES2408132B1 (es) * 2010-09-08 2014-04-04 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento de la epífora.
ES2377785B2 (es) 2010-09-08 2012-09-26 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento del ojo seco.
WO2012121988A2 (en) * 2011-03-07 2012-09-13 Celgene Corporation Methods for treating diseases using isoindoline compounds
CN102793684B (zh) * 2011-05-26 2016-02-17 杭州赛利药物研究所有限公司 罗氟司特液体制剂及其制备方法
AU2012277905A1 (en) * 2011-06-28 2014-01-16 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing regorafenib
US9951335B2 (en) * 2012-04-10 2018-04-24 Georgia State University Research Foundation, Inc. Compositions and methods for treating otitis media and other conditions with inhibitors of CYLD
CN103570610B (zh) * 2012-07-18 2017-08-11 重庆华邦制药有限公司 一种罗氟司特微粒的制备方法
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
KR20150079745A (ko) 2012-11-08 2015-07-08 리젠 파마슈티컬스 소시에떼 아노님 Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물
CA2921308A1 (en) 2013-08-16 2015-02-19 Universiteit Maastricht Treatment of cognitive impairment with pde4 inhibitor
CN105434328A (zh) * 2014-09-01 2016-03-30 天津药物研究院有限公司 一种含罗氟司特固体分散体的固体制剂及其制备方法
ES2777550T3 (es) 2014-10-24 2020-08-05 Hisamitsu Pharmaceutical Co Profármaco de roflumilast
CN104997959A (zh) * 2015-08-21 2015-10-28 蔡宇平 一种用于治疗睑板腺囊肿的中药
CN106148528B (zh) * 2016-07-11 2019-10-01 赵晨 一种遗传性Usher综合征的致病突变及其检测试剂
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en) * 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20200155524A1 (en) * 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11534493B2 (en) * 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CN108283620A (zh) * 2018-03-13 2018-07-17 兆科药业（广州）有限公司 一种磷酸二酯酶-4抑制剂的局部药物组合物及其制备方法
JP7492918B2 (ja) 2018-06-04 2024-05-30 アーキュティス・バイオセラピューティクス・インコーポレーテッド ロフルミラスト皮膚浸透ラグタイムを改善する方法及び配合物
KR102117525B1 (ko) * 2018-07-09 2020-06-01 건양대학교 산학협력단 Pde4b 저해제를 유효성분으로 함유하는 만성 부비동염에서의 비용종 발생의 예방 및 치료용 약학 조성물
WO2021155173A1 (en) 2020-01-31 2021-08-05 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half-life
MX2022008735A (es) * 2020-05-07 2022-09-19 Arcutis Biotherapeutics Inc Tratamiento de condiciones de la piel usando tensioactivos anionicos de alta temperatura de krafft.
WO2022169615A1 (en) 2021-02-05 2022-08-11 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
MX2023009352A (es) * 2021-02-10 2023-08-16 Iolyx Therapeutics Inc Metodos para la administracion oftalmica de roflumilast.
CN116867480A (zh) * 2021-02-10 2023-10-10 洛利克斯治疗有限公司 眼部递送罗氟司特的方法
EP4351612A2 (en) * 2021-06-01 2024-04-17 Eyedea Bio, Llc Extended release drug delivery system for ocular drugs and methods of use
WO2024058848A1 (en) 2022-09-15 2024-03-21 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug
WO2025054483A1 (en) 2023-09-07 2025-03-13 Arcutis Biotherapeutics, Inc. Dosing regimens using topical roflumilast compositions
US20250090508A1 (en) 2023-09-15 2025-03-20 Arcutis Biotherapeutics, Inc. Methods of reducing itch using topical roflumilast compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753945A (en) * 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US5011843A (en) * 1988-05-31 1991-04-30 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
US5891904A (en) * 1992-09-14 1999-04-06 Wolf-Georg Forssmann Use of inhibitors of phosphodiesterase IV
SK283263B6 (sk) * 1993-07-02 2003-04-01 Altana Pharma Ag Fluóralkoxysubstituované benzamidy, spôsob ich výroby a ich použitie ako inhibítorov fosfodiesterázy cyklických nukleotidov
KR960703621A (ko) * 1993-08-10 1996-08-31 후지야마 아키라 경피흡수 제제(Percutaneously absorbable preparation)
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
TR200200971T2 (tr) * 1998-09-29 2002-06-21 Fujisawa Pharmaceutical Co., Ltd. Piridopirazan bileşiğinin yeni tuzları ve bunların kristalleri.
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US20020006418A1 (en) * 1998-10-13 2002-01-17 John Kung Composition to enhance permeation of topical skin agents
AU3284000A (en) 1999-03-10 2000-09-28 Byk Gulden Lomberg Chemische Fabrik Gmbh 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid- 4-yl)benzamide in the treatment of multiple sclerosis
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
DZ3249A1 (fr) * 1999-10-29 2001-05-10 Smithkline Beecham Corp Procédé d'administration d'un inhibiteur phosphodiesterase 4
GEP20043385B (en) * 2000-01-31 2004-04-13 Pfizer Prod Inc Pyrimidine Carboxamides Useful as Inhibitors of PDE4 Isozymes, Pharmaceutical Compositions Containing the Same
WO2001060358A1 (en) * 2000-02-16 2001-08-23 University Of Nebraska Medical Center Method and compositions for treating fibrotic diseases
AU6196201A (en) * 2000-05-25 2001-12-03 Merck Frosst Canada Inc Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
WO2002038155A1 (en) * 2000-11-07 2002-05-16 Merck & Co., Inc. Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
UA77656C2 (en) * 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6872382B1 (en) * 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
US20030092706A1 (en) * 2001-11-09 2003-05-15 Johannes Barsig Combination
CN101491520B (zh) * 2002-05-28 2011-03-16 尼科梅德有限责任公司 局部应用的药物制剂

Also Published As

Publication number Publication date
CN1655782A (zh) 2005-08-17
NO20045656L (no) 2004-12-27
NO334882B1 (no) 2014-06-30
AU2003240719A1 (en) 2003-12-12
HRP20041211B1 (hr) 2013-06-30
RS51104B (sr) 2010-10-31
UA88523C2 (ru) 2009-10-26
PL211870B1 (pl) 2012-07-31
EP1511516B1 (en) 2008-12-17
NZ536920A (en) 2007-04-27
US20080280958A1 (en) 2008-11-13
AU2003232828B2 (en) 2010-06-24
MA27813A1 (fr) 2006-04-03
JP2012229245A (ja) 2012-11-22
EA010416B1 (ru) 2008-08-29
CA2486910A1 (en) 2003-12-04
CN101491520A (zh) 2009-07-29
BR0311337A (pt) 2005-03-15
KR20050014844A (ko) 2005-02-07
EA020569B1 (ru) 2014-12-30
MXPA04011528A (es) 2005-02-14
WO2003099278A1 (en) 2003-12-04
EP1511481A1 (en) 2005-03-09
UA81910C2 (uk) 2008-02-25
JP5683538B2 (ja) 2015-03-11
ATE417628T1 (de) 2009-01-15
LT2020243T (lt) 2018-11-12
CY1121133T1 (el) 2019-12-11
IL164935A (en) 2010-12-30
EP2020243A1 (en) 2009-02-04
PL397021A1 (pl) 2012-03-26
CN101491520B (zh) 2011-03-16
HUE039709T2 (hu) 2019-01-28
CA2486917A1 (en) 2003-12-04
ME00565A (en) 2011-12-20
PL372095A1 (en) 2005-07-11
DK1511481T3 (da) 2011-01-24
ZA200409584B (en) 2006-05-31
EA200401517A1 (ru) 2005-06-30
IS7612A (is) 2004-12-23
ATE485821T1 (de) 2010-11-15
MXPA04011612A (es) 2005-03-07
CN1655823B (zh) 2010-05-26
RS101404A (en) 2007-02-05
SI1511516T1 (sl) 2009-06-30
WO2003099334A1 (en) 2003-12-04
KR20110122230A (ko) 2011-11-09
ES2693094T3 (es) 2018-12-07
US20110313005A1 (en) 2011-12-22
IL209657A0 (en) 2011-02-28
IL165065A0 (en) 2005-12-18
CA2486910C (en) 2011-11-29
US20060084685A1 (en) 2006-04-20
CA2486917C (en) 2011-11-22
IS2639B (is) 2010-06-15
ES2319517T3 (es) 2009-05-08
NZ553731A (en) 2007-07-27
IL165065A (en) 2010-11-30
DK2020243T3 (en) 2018-11-19
DE60325354D1 (de) 2009-01-29
PT1511516E (pt) 2009-02-20
ZA200408649B (en) 2007-12-27
HRP20041211A2 (hr) 2006-04-30
NZ537308A (en) 2009-09-25
EP1511481B1 (en) 2010-10-27
DE60334692D1 (de) 2010-12-09
US20190029956A1 (en) 2019-01-31
NO334916B1 (no) 2014-07-14
PT1511481E (pt) 2011-01-14
EP1511516A1 (en) 2005-03-09
CN100490804C (zh) 2009-05-27
ES2354971T3 (es) 2011-03-21
SI2020243T1 (sl) 2018-11-30
AU2003240719B2 (en) 2009-12-10
EA200702588A1 (ru) 2008-08-29
CN1655823A (zh) 2005-08-17
HK1079437A1 (en) 2006-04-07
BR0311339A (pt) 2005-03-22
JP2005529930A (ja) 2005-10-06
HK1079445A1 (en) 2006-04-07
KR101307093B1 (ko) 2013-09-11
AU2003232828A1 (en) 2003-12-12
DK1511516T3 (da) 2009-04-06
US20210116207A1 (en) 2021-04-22
TR201815573T4 (tr) 2018-11-21
PT2020243T (pt) 2018-11-09
JP2005529928A (ja) 2005-10-06
EP2020243B1 (en) 2018-08-15
NO20045506L (no) 2004-12-16
US20060084684A1 (en) 2006-04-20
PL372082A1 (en) 2005-07-11
US20140303215A1 (en) 2014-10-09
PL212134B1 (pl) 2012-08-31
IL164935A0 (en) 2005-12-18
JP5652983B2 (ja) 2015-01-14

Similar Documents

Publication Publication Date Title
CY1121133T1 (el) Τοπικα εφαρμοσιμο φαρμακευτικο παρασκευασμα
NO20032510L (no) Organiske forbindelser
AU2002211863A1 (en) Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
CY1111851T1 (el) Αρωματικες ενωσεις ως αντι-φλεγμονωδεις, ανοσορυθμιστικοι και αντι-πολλαπλασιαστικοι παραγοντες
ATE337016T1 (de) Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
ECSP045447A (es) Preparación farmacéutica que se puede aplicar por vía tópica